Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days
NCT ID: NCT00686179
Last Updated: 2008-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
75 participants
INTERVENTIONAL
2008-01-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart
NCT01222442
Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects
NCT00672399
Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers
NCT02217930
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
NCT02056392
Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval
NCT00713336
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Escalating doses of AZD3480 during 6 days
AZD3480
Capsule, oral, single dose, 6 days
2
Repeated doses of AZD3480 during 6 days
AZD3480
Capsule, oral, single dose, 6 days
3
Placebo during 6 days
PLACEBO
Capsule, oral, single dose
4
Placebo during 5 days, active day 6
Moxifloxacin
Capsule(encapsulated), oral, single dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD3480
Capsule, oral, single dose, 6 days
Moxifloxacin
Capsule(encapsulated), oral, single dose
PLACEBO
Capsule, oral, single dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physically and mentally healthy male volunteers
Exclusion Criteria
* Participation in another study the last 3 months
* Prescribed or non-prescribed medications from 3 weeks prior to first treatment day until follow-up except for paracetamol (max 1.5 g per day.)
20 Years
60 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca R&D, Södertälje, Sweden
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hans-Göran Hårdemark
Role: STUDY_DIRECTOR
Clinical Neuroscience TA AstraZeneca R&D Södertälje, Sweden
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUdract NO 2007-004859-11
Identifier Type: -
Identifier Source: secondary_id
D3690C00004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.